Anika Therapeutics, Inc. Discontinued Operation, Tax Effect of Discontinued Operation
Anika Therapeutics, Inc. (ANIK) reported Discontinued Operation, Tax Effect of Discontinued Operation of $0 for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation · last filed 2026-07-29
- Anika Therapeutics, Inc. discontinued operation, tax effect of discontinued operation for the quarter ending 2026-06-30 was $0.00.
- Anika Therapeutics, Inc. discontinued operation, tax effect of discontinued operation for the quarter ending 2025-12-31 was $1.51M.
- Anika Therapeutics, Inc. discontinued operation, tax effect of discontinued operation for the quarter ending 2025-09-30 was -$845.00K, a 725.93% decline year-over-year.
- Anika Therapeutics, Inc. discontinued operation, tax effect of discontinued operation for the quarter ending 2025-06-30 was -$663.00K.
- Anika Therapeutics, Inc. discontinued operation, tax effect of discontinued operation for fiscal 2025 was $0.00.
- Anika Therapeutics, Inc. discontinued operation, tax effect of discontinued operation for fiscal 2024 was -$417.00K.
- Anika Therapeutics, Inc. discontinued operation, tax effect of discontinued operation for fiscal 2023 was -$9.26M.
| Period end | Discontinued Operation, Tax Effect of Discontinued Operation 3 month | Discontinued Operation, Tax Effect of Discontinued Operation 6 month | Discontinued Operation, Tax Effect of Discontinued Operation 9 month | Discontinued Operation, Tax Effect of Discontinued Operation 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-07-29 | $0.00 10-Q · filed 2026-07-29 | ||
| 2025-12-31 | $1.51M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $663.00K derived: sum of 2 quarters · filed 2026-03-03 | $0.00 derived: sum of 3 quarters · filed 2026-07-29 | $0.00 10-K · filed 2026-03-03 |
| 2025-09-30 | -$845.00K 10-Q · filed 2025-11-05 | -$1.51M derived: sum of 2 quarters · filed 2026-07-29 | -$1.51M 10-Q · filed 2025-11-05 | |
| 2025-06-30 | -$663.00K 10-Q · filed 2026-07-29 | -$663.00K 10-Q · filed 2026-07-29 | ||
| 2024-12-31 | -$71.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $64.00K derived: sum of 2 quarters · filed 2026-03-03 | -$417.00K derived: sum of 3 quarters · filed 2026-03-03 | -$417.00K 10-K · filed 2026-03-03 |
| 2024-09-30 | $135.00K 10-Q · filed 2025-11-05 | -$346.00K derived: sum of 2 quarters · filed 2025-11-05 | -$346.00K 10-Q · filed 2025-11-05 | |
| 2024-06-30 | -$481.00K 10-Q · filed 2025-07-30 | -$481.00K 10-Q · filed 2025-07-30 | ||
| 2023-12-31 | -$9.26M 10-K · filed 2026-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| Neuronetics, Inc. (STIM) | United States | $0.216B | -3.25 |